Pre-clinical data suggests Noxopharm’s anti-cancer drug can boost radiation effect on paediatric bra

Pre-clinical data has confirmed Noxopharm’s (ASX: NOX) experimental idronoxil anti-cancer drug can boost the killing effect of radiation when treating paediatric brain cancer cells.

Read more: https://smallcaps.com.au/pre-clinical-data-noxopharm-drug-radiation-paediatric-brain-cancer/